SLC5A2 and chronic kidney disease: In addition to RAS blockade, SGLT2 inhibitors and bicarbonate therapy have proved to retard CKD progression, and new drugs targeting fibrosis and inflammation, as well as regenerative therapy may enhance these effects in our goal to mitigate CKD progression and consequently cardiovascular and global mortality.